First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.

T, Liu; Y, Bai; X, Lin; W, Li; J, Wang; X, Zhang; H, Pan; C, Bai; L, Bai; Y, Cheng; J, Zhang; H, Zhong; Y, Ba; W, Hu; R, Xu; W, Guo; S, Qin; N, Yang; J, Lu; K, Shitara; M, Lei; M, Li; N, Bao; T, Chen; L, Shen

doi:10.1002/ijc.34296

Public

First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.

Shared by NobleBlocks on Oct 31, 2022 • 12:00 AM UTC

Authors:

Liu T

Bai Y

Lin X

Abstract

First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 64...

Subject

Stomach neoplasms

Immunotherapy

Gastrointestinal neoplasms

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!